Bufexamac (Standard)
Bufexamac (Standard) is the analytical standard of Bufexamac. This product is intended for research and analytical applications. Bufexamac is a selective IIb HDAC (HDAC6, HDAC10) and LTA4H dual inhibitor, with Kds of 0.53 μM and 0.22 μM for HDAC6 and HDAC10. Bufexamac is a nonsteroida anti-inflammatory drug[1][2][3].
Product Specifications
CAS Number
2438-72-4
Product Name Alternative
Bufexamic acid (Standard)
UNSPSC
12352005
Target
Aminopeptidase; HDAC; Reference Standards
Type
Reference Standards
Related Pathways
Cell Cycle/DNA Damage; Epigenetics; Metabolic Enzyme/Protease; Others
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/bufexamac-standard.html
Smiles
O=C(NO)CC1=CC=C(OCCCC)C=C1
Molecular Formula
C12H17NO3
Molecular Weight
223.27
References & Citations
[1]Bantscheff M, et al. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat Biotechnol. 2011 Mar;29 (3) :255-65.|[2]Oehme I, et al. Histone deacetylase 10 promotes autophagy-mediated cell survival. Proc Natl Acad Sci U S A. 2013 Jul 9;110 (28) :E2592-601.|[3]Xiao Q, et al. Bufexamac ameliorates LPS-induced acute lung injury in mice by targeting LTA4H. Sci Rep. 2016 Apr 29;6:25298. |[4]Schölz C, et al. Acetylation site specificities of lysine deacetylase inhibitors in human cells. Nat Biotechnol. 2015 Apr;33 (4) :415-23.|[5]Suominen MM, et al. Effects of intra-articular injections of bufexamac suspension in healthy horses. Am J Vet Res. 2001 Oct;62 (10) :1629-35.
Shipping Conditions
Room temperature
Scientific Category
Reference Standards
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
